Skip to content

Kalydeco Wins In Northern Ireland

March 13, 2013

On March 12, 2013, it is announced that the National Health Service (NHS) in Northern Ireland is to provide Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) for patients with Cystic Fibrosis (CF), ages 6+ and who have at least one copy of the G551D mutation. According to a BBC article, there are approximately 500 CF patients in Northern Ireland with about 7% of them having the G551D mutation. Kalydeco would benefit 30-35 CF patients in Northern Ireland. The drug carries a list price of £182,625 per patient per year.

According to Vertex Pharmaceuticals’ March 12, 2013 statement, Kalydeco funding decisions have been made in :

  1. England
  2. Scotland
  3. Northern Ireland
  4. Republic of Ireland.

The Health Technology Appraisal (HTA) is ongoing with the relevant authorities in Wales. Kalydeco is commercially available in France and Germany and reimbursement negotiations are progressing.

Media Coverage On Kalydeco in Northern Ireland

1)  BBC News article titled, “Drug breakthrough for NI cystic fibrosis sufferers”

2)  Newsletter UK article titled, “New Cystic Fibrosis drug approved”.


CF Trust UK March 12, 2013 announcement

Northern Ireland Executive March 12, 2013 announcement

Vertex Pharmaceuticals March 12, 2013 statement.

Please Note: “Icon Announcer” by Orion 8 [Public domain] | Wikimedia Commons.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: